Table 3.
Patient characteristics of the SFHN patients with hypertension at the start of BID-SF
| Pilot site | Other SFHN clinics | |
|---|---|---|
| Total number of patients with HTN | 2,449 | 13,468 |
| Demographics | N (%) | N (%) |
| Age (mean, sd) | 61.1 (11.2) | 59.8 (10.8) |
| 20 – 34 | 43 (1.8) | 310 (2.3) |
| 35 – 64 | 1493 (61.0) | 8811 (65.4) |
| 65 – 79 | 734 (32.0) | 3918 (29.1) |
| 80 – 85 | 129 (5.3) | 429 (3.2) |
| Female | 1201 (49.0) | 7017 (52.1) |
| Race | ||
| White | 376 (15.4) | 2335 (17.3) |
| Black | 496 (20.3) | 3101 (23.0) |
| Asian | 718 (29.3) | 4788 (35.6) |
| Hispanic | 747 (30.5) | 2783 (20.7) |
| Other | 112 (4.6) | 459 (3.4) |
| Medical history | ||
| Diabetes | 1119 (46.1) | 4849 (36.0) |
| Chronic kidney disease | 446 (18.2) | 2912 (21.6) |
| Blood Pressure | ||
| Mean systolic BP (SD) | 132.5 (19.6) | 133.8 (17.8) |
| Mean diastolic BP (SD) | 77.3 (10.9) | 79.8 (13.6) |
| Uncontrolled hypertension‡ | 856 (35.0) | 4654 (34.6) |
| Stage of uncontrolled hypertension | ||
| Stage I: 140 – 159/90 – 99 | 616 (72.0) | 3304 (71.0) |
| Stage 2: 160 – 179/100 – 109 | 188 (22.0) | 1047 (22.5) |
| Severe HTN: ≥ 180/≥110 | 52 (6.07) | 303 (6.5) |
| Prevalence of Resistant hypertension‖ | 507(20.0) | 2038 (15.9) |
| Uncontrolled HTN on ≥ 3 BP medications | 300 (59.2) | 1187 (58.2) |
| # of antihypertensive medications (mean, sd) | 2.08 (1.3) | 1.90 (1.2) |
| 0 | 227 (8.9) | 1634 (12.8) |
| 1 | 654 (25.8) | 3329 (26.0) |
| 2 | 793 (31.2) | 4113 (32.1) |
| 3+ | 865 (34.1) | 3725 (29.1) |
RFPC = Richard Fine People’s Clinic at the Zuckerberg San Francisco General Hospital
SFHN = San Francisco Health Network
Percentages are reported as column %
The start of BID-SF is 08/2014 for SFPC and 05/2015 for the other 11 SFHN clinics
uncontrolled hypertension per 2014 guidelines: BP ≥150/90 for patients 60 or older without CKD or diabetes and BP ≥140/90 for all other patients
Resistant hypertension: patient on ≥ 4 BP medications or has uncontrolled hypertension with 3 BP medications at presentation
Note: Because meds data are not available for baseline months, prevalence of resistant HTN and med counts are as of Dec 2014 for the pilot site (n=2539) and Feb 2016 for SFHN (n=12801), respectively